Skip to main content

AMA Launches Common Data Model Initiative

The American Medical Association (AMA) has launched a collaborative of healthcare industry stakeholders to create a "common data model." Called the Integrated Health Model Initiative (IHMI), the program is intended to make it easier to pull together a wide variety of patient data in a structured format and exchange it among electronic health records (EHRs) from different companies.
Participation in IHMI is open to all healthcare and technology stakeholders. Early collaborators include IBM, Cerner, Intermountain Healthcare, the American Heart Association, and the American Medical Informatics Association, among others. The participants will interact in an online platform hosted by the AMA.
"We spend more than three trillion dollars a year on health care in America and generate more health data than ever before. Yet some of the most meaningful data — data to unlock potential improvements in patient outcomes — is fragmented, inaccessible or incomplete," said AMA CEO James L. Madara, MD, in a statement. "The collaborative effort of IHMI will help the health system learn how to collect, organize, and exchange patient-centered data in a common structure that captures what is most important for improving care and long-term wellness, and transform the data into a rich stream of accessible and actionable information."
Initially, IHMI will focus on three areas:
  • Hosting clinical and issue-based communities that address costly and burdensome areas. The initial priority of these communities will be the development of data elements for chronic conditions such as hypertension, diabetes, and asthma.
  • Creating a clinical validation process to determine and apply appropriate clinical frameworks. Participants will provide contributions and feedback online to specify data elements and relationships. Clinical content submissions will go through a validation process to review their clinical applicability.
  • Specifying a model to encode information in the IHMI data model. The clinical content will enable configurations of the model and reference value sets that will be made available for free.

"Best Minds in Healthcare"

Laurie McGraw, senior vice president of health solutions for the AMA and the lead on the IHMI project, told Medscape Medical News that the AMA wants to organize healthcare data better, turn more of it into usable information, and expand beyond the current boundaries of coded clinical data such as diagnostic and procedure codes. The goal, she said, is to include patient-reported information such as mobile device data and functional status data, plus data on social determinants of health.
The common data model will also establish standard terms for medical concepts that can be described in many different ways, McGraw said. She added that the AMA is working closely with SNOMED, the organization that maintains SNOMED-CT, the most complete lexicon of medical terms.
The importance of this component was underlined by David McCallie, MD, senior vice president for medical informatics at Cerner, who said in a statement that IHMI is designed "to improve the semantics of clinical data models. This represents a bold attempt to advance an important aspect of interoperability."
Stan Huff, MD, chief medical informatics officer of Intermountain Healthcare, said in a statement, "I am excited about IHMI because it builds on the foundation of interoperability standards that are being created by HL7, LOINC, and SNOMED International. If we persist, that approach will lead to the ability to exchange medical knowledge as executable software rather than as journal articles."
The AMA expects EHR vendors to incorporate IHMI into their software at some point, McGraw said. So far, only Cerner and Care Cloud, a small EHR vendor, have joined the project. But she said she is confident many other software developers will come aboard.
McGraw acknowledged that a lot of resources will be required to validate clinical data elements, encode the data as specified by the data model, and so forth. But she noted that the AMA has a team of in-house informaticists and that it will also rely on help from other IHMI participants.
Regarding clinical validation, she pointed out, the AMA produces Current Procedural Terminology codes, which must be constantly updated for new medical knowledge. "A volunteer army of the best minds in healthcare" works together to make sure this is done right, she said.
The AMA has been trying to get physicians more involved in the development of health information technology (IT) applications for some time. In January 2016, for example, the association invested $15 million in Health2047, a San Francisco-based "innovation enterprise" that develops new applications and work with established companies to fine-tune their health IT products. Later that year, the AMA adopted principles to promote the use of "safe and effective" mobile health apps and related devices.

Comments

Post a Comment

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Sitting at Work Raises All-Cause and CV Mortality Risk

May 21, 2012 (Lyon, France) — Sitting at work raises the risk of dying from cardiovascular (CV) and metabolic diseases, as well as the risk of dying from all causes, regardless of any exercise in which the individual may engage. That was the finding of a study reported here at the 19th European Congress on Obesity (ECO) by Anne Grunseit, PhD, from the Prevention Research Collaboration in the School of Public Health at the University of Sydney, Australia, and Norwegian colleagues. Research is increasingly focusing on sedentary behavior with low energy expenditure, including sitting and lying down, as behavioral risk factors for obesity and chronic disease. Sitting occurs during travel, while watching television, using computers, and reading. But with people often spending at least 9 hours a day at work, with fewer than 20% of jobs requiring physical exertion, and with many people spending at least 4 hours a day sitting at work, the sedentary time at work is high, and many people ar...
Post a Comment
Read more